NICE Cardiology Guidance Under the Microscope: A Data-Driven Statistical Critique

Abstract

Can transparent, reproducible meta-analysis reveal how quickly national guideline bodies translate cardiovascular trial evidence into practice? We assembled twenty Phase 3 SGLT2-inhibitor trials and seven post-ACS lipid trials, cross-referencing the trials registry, EMA/FDA/WHO timelines, NHS prescribing data, and six guideline bodies. For the class effect we pooled the eight pivotal trials reporting the cardiovascular-death-or-heart-failure-hospitalisation composite with a random-effects hazard-ratio model, cross-validated in R metafor and WebR. The pooled class-effect hazard ratio was 0.79 (95% CI 0.74–0.84), a 21% risk reduction, with low heterogeneity (I² 8%) and Monte-Carlo reversal probability below 0.1%. Among the six bodies compared, NICE was the slowest to adopt SGLT2 inhibitors for heart failure, trailing its European and North-American counterparts. The benefit was statistically robust and consistent across the diabetes, heart-failure, and chronic-kidney-disease populations, yet appraisal-driven national adoption lagged the evidence. This analysis of public aggregate data cannot account for unpublished NICE cost-effectiveness deliberations that may justify part of the observed delay.